Pharmicell Co.,Ltd.
Financials
Valuation Metrics
Pharmicell Co.,Ltd.'s Market Cap is ₩6648B. At end of 2025 it was ₩8719B. Ranked #368 of 2,436 in KR market (top 15%), #249 of 787 on KOSPI (top 32%), #41 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 18%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 664.84B KRW | KR#368/2,436 Sec#41/234 |
| Revenue | 123.72B KRW | KR#1,278/2,436 Sec#80/234 |
| Net Income | 43.54B KRW | KR#408/2,436 Sec#27/234 |
| Total Assets | 168.10B KRW | KR#1,390/2,436 Sec#110/234 |
| Net Assets | 132.78B KRW | KR#1,191/2,436 Sec#95/234 |
| Employees | 146 | KR#1,341/2,436 Sec#109/234 |
| Value | ||
| P/E | 15.27x | KR#990/2,436 Sec#61/234 |
| P/B | 5.01x | KR#2,238/2,436 Sec#186/234 |
| PEG | 0.40x | KR#640/2,436 Sec#37/234 |
| P/S | 5.37x | KR#2,156/2,436 Sec#143/234 |
| EV/EBITDA | 16.97x | KR#926/2,436 Sec#54/234 |
| FCF Yield | 5.05% | KR#865/2,436 Sec#43/234 |
| Profitability | ||
| ROE | 32.79% | KR#40/2,436 Sec#2/234 |
| ROA | 25.90% | KR#15/2,436 Sec#1/234 |
| Op. Margin | 31.52% | KR#45/2,436 Sec#11/234 |
| Revenue Growth | 35.75% | KR#409/2,436 Sec#37/234 |
| Earnings Growth | 38.44% | KR#633/2,436 Sec#38/234 |
| Financial Health | ||
| Debt Ratio | 126.60% | KR#792/2,436 Sec#93/234 |
| Total Debt | 19.94B KRW | KR#1,362/2,436 Sec#112/234 |
| FCF | 33.60B KRW | KR#387/2,436 Sec#22/234 |
| Cash | 22.88B KRW | KR#1,158/2,436 Sec#82/234 |
| Current Ratio | 6.86x | KR#190/2,436 Sec#43/234 |
| Net Debt/EBITDA | -0.08x | KR#671/2,436 Sec#41/234 |
| Dividend | ||
| Div. Yield | 0.49% | KR#1,291/2,436 Sec#84/234 |
| Div. Growth | 150.00% | KR#61/2,436 Sec#2/234 |
| Performance | ||
| 1Y Return | -10.06% | KR#965/2,436 Sec#70/234 |
| 1M Return | -10.28% | KR#1,776/2,436 Sec#180/234 |
| From 52W High | -47.61% | KR#1,082/2,436 Sec#90/234 |
| 1Y MDD | -56.74% | KR#1,236/2,436 Sec#99/234 |
| Trading | ||
| Volume | 660,866 shares | KR#207/2,436 Sec#16/234 |
| Foreign Own. | 11.84% | KR#419/2,436 Sec#38/234 |
| Per Share | ||
| EPS | 725 KRW | KR#758/2,436 Sec#55/234 |
| BPS | 2,213 KRW | KR#1,980/2,436 Sec#163/234 |
Company Info
Pharmicell, established in 1968 and renamed in 2011, is a specialized biotech company listed in 1988. It operates a biomedical division, manufacturing and selling the world's first stem cell therapy, and a biochemical division, producing pharmaceutical intermediates and eco-friendly phosphorus flame retardants, in addition to stem cell banking and cosmetics businesses. The company has developed and patented technologies for anticancer immunotherapy dendritic cells and neurological disorder treatments. Pharmicell is actively pursuing innovation through technology development in areas such as mRNA vaccine raw materials and artificial blood, and is headquartered in Gangnam-gu, Seoul.